Welcome to our dedicated page for Akoya Biosciences news (Ticker: AKYA), a resource for investors and traders seeking the latest updates and insights on Akoya Biosciences stock.
Akoya Biosciences, Inc. (AKYA), known as The Spatial Biology Company®, generates news that spans technology developments, collaborations, financial reporting, and corporate transactions. Company announcements emphasize its single-cell imaging and spatial proteomics platforms, which are used to phenotype cells with spatial context and study how they organize and interact in disease. News items often describe how Akoya’s PhenoCode™ Panels, PhenoCycler®, Phenor® Fusion, and Phenor HT instruments are applied across discovery, translational, and clinical research.
Investors and researchers following AKYA-related news will find updates on spatial biology and proteomics initiatives, including large-scale projects and partnerships. Recent releases highlight collaborations such as the Cancer Grand Challenges-funded study using PhenoCycler-Fusion, the SUPER study with the Singapore Translational Cancer Consortium leveraging the IO60 panel to investigate PD-1 immunotherapy response, and the Enable Medicine Pan-Cancer Atlas built on Akoya’s PhenoCycler-Fusion and IO60 technologies. These stories illustrate how Akoya’s platforms are integrated into biomarker discovery, drug development, and precision oncology efforts.
News coverage has also included financial results and operational updates, such as quarterly revenue composition, changes in operating expenses, and growth in the installed base of instruments and publications citing Akoya’s technology. In addition, corporate and capital markets news has been prominent, particularly the Amended and Restated Agreement and Plan of Merger with Quanterix Corporation and subsequent shareholder and activist responses to that transaction.
Following the completion of the merger on July 8, 2025, Akoya became a wholly owned subsidiary of Quanterix, and its common stock was removed from listing on Nasdaq. The AKYA news stream therefore serves as a historical archive of Akoya’s activities as an independent public company, covering its evolution in spatial biology, its collaborations, and the steps leading to its acquisition by Quanterix.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has launched the PhenoCycler™-Fusion system, revolutionizing spatial biology with its ability to map a million cells in just 10 minutes. This integrated platform combines high-speed imaging and ultrahigh multiplex cycling, allowing researchers to conduct large-scale biomarker discovery and validation efficiently. It can process over 300 samples weekly and incorporates RNA detection for comprehensive tissue analysis. The system enhances existing products, promising unbiased, rapid mapping of cellular interactions related to diseases.
Akoya Biosciences, Inc. (Nasdaq: AKYA) announced preliminary unaudited revenues for Q4 and full year 2021, with Q4 revenue expected between $16.0 million and $16.2 million, up from $12.9 million in Q4 2020. Full year revenue forecasts are between $54.8 million and $55.0 million, compared to $42.4 million in 2020. CEO Brian McKelligon highlighted significant progress, including a 30% revenue growth, an IPO, and near doubling of the company’s workforce. Despite these positive indicators, actual results remain subject to quarter-end adjustments.
Akoya Biosciences partners with Bio-Techne to develop the first single-cell, spatial multiomics workflow, enhancing the analysis of tissue samples. The PhenoCycler™-Fusion system, launching early January 2022, will automate protein and RNA imaging through RNAScope® technology. This collaboration aims to accelerate research in human health and complex diseases, offering new biomarker diagnostic signatures and improving treatment outcomes. Over 4,500 peer-reviewed publications back RNAScope assays, establishing them as a standard for spatial RNA imaging.
Bio-Techne (NASDAQ: TECH) and Akoya Biosciences (NASDAQ: AKYA) announced a partnership to develop a groundbreaking automated spatial multiomics workflow for tissue sample analysis. The collaboration aims to enhance RNA and protein analysis at single-cell resolution, facilitating better biomarker discovery and patient stratification in diseases like cancer. The partnership leverages Akoya's PhenoCycler-Fusion System and Bio-Techne's RNAScope HiPlex v2 assay, promising to accelerate research and improve treatment outcomes for complex diseases.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced its participation in the 40th Annual J.P. Morgan Healthcare Conference, scheduled for January 13, 2022, at 9:00 a.m. ET. Brian McKelligon, CEO, will present the company's insights and developments. Investors can access both live and archived webcasts of this event through the Akoya website. As a leader in spatial biology, Akoya aims to enhance understanding of human health and disease through its innovative single-cell imaging solutions, including the CODEX® and Phenoptics™ platforms.
Akoya Biosciences, Inc. (Nasdaq: AKYA) has announced a suite of innovations aimed at enhancing spatial biology research. Key highlights include the launch of the PhenoCycler-Fusion System, which enables mapping a million cells in under 10 minutes. The system combines ultrahigh multiplex cycling technology and high-speed imaging, allowing for faster and more detailed spatial discovery. Akoya will also introduce novel RNA and protein chemistries, facilitating comprehensive multiomic assessment. The commercial launch of the PhenoCycler-Fusion is set for January 2022, following limited distribution in December 2021.
Akoya Biosciences (Nasdaq: AKYA) and PathAI have partnered to enhance the discovery of predictive biomarkers for immunotherapies. This collaboration utilizes Akoya's Phenoptics™ spatial phenotyping platform and PathAI's AI algorithms to aid biopharmaceutical companies in identifying patients likely to respond to clinical trial treatments. The partnership aligns with Akoya's recent CLIA certification and aims to revolutionize cancer treatment through improved efficacy rates in immuno-oncology. Key insights into tumor microenvironments will accelerate drug development and clinical trials.
Akoya Biosciences (Nasdaq: AKYA) has achieved CLIA certification for its Advanced Biopharma Solutions laboratory in Marlborough, Massachusetts. This certification allows Akoya to support later-stage clinical trials and enhances its ability to develop and validate assays to meet high-quality standards. The certification positions Akoya as a valuable partner to biopharmaceutical companies, particularly in cancer immunotherapy. This advance follows prior milestones, including a publication demonstrating Akoya's spatial biology technology's effectiveness in clinical settings.
Akoya Biosciences, known as The Spatial Biology Company, will hold its inaugural Spatial Day on December 15, 2021, at 12 p.m. ET. This event will showcase recent advancements in spatial biology, emphasizing its potential in discovery and clinical research. Key speakers include Akoya's CEO Brian McKelligon and leading experts from renowned institutions. Topics will cover disease biology and the future role of spatial biomarkers in transforming healthcare solutions. Interested participants can register at www.akoyabio.com/spatialday.
Akoya Biosciences (AKYA) reported record Q3 2021 revenue of $13.5 million, a 35% increase year-over-year. Product revenue reached $10.9 million, up 38%, while services generated $2.6 million. Gross profit surged to $8.5 million with a margin of 62.7%. The company installed 33 instruments in Q3, contributing to a total of 651 instruments worldwide. With $120.2 million in cash, Akoya maintains strong growth momentum and raised its full-year revenue guidance to at least $53.8 million.
FAQ
What is the current stock price of Akoya Biosciences (AKYA)?
What is the market cap of Akoya Biosciences (AKYA)?
